Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18592218 | 0.89 | DRD2 (0.40) | DRD2SLC18A3HTR1ADRD1DRD5 | |
| SCHEMBL22419324 | 0.80 | POLB (0.43) | DRD2HRH1HTR1AHTR2ADRD3 | |
| SCHEMBL22965358 | 0.78 | CARM1 (0.45) | DRD2SLC18A3HTR1ADRD1DRD5 | |
| SCHEMBL13612743 | 0.77 | DRD2 (0.69) | DRD2HRH1SLC18A3 | |
| SCHEMBL23664608 | 0.75 | HRH3 (0.41) | DRD2HRH1SLC18A3HRH3CYP2C9 | |
| SCHEMBL27296352 | 0.72 | DRD2 (0.65) | DRD2SLC18A3 | |
| SCHEMBL26748716 | 0.71 | KDM4E (0.41) | — | |
| SCHEMBL24654217 | 0.70 | LTA4H (0.38) | HRH3CYP2C9 | |
| SCHEMBL25654120 | 0.69 | TLR9 (0.48) | DRD2HRH1TLR9TLR8TLR7 | |
| SCHEMBL18591747 | 0.69 | DRD4 (0.41) | DRD2HRH1HTR1AHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | DRD2 580/4885HRH1 573/4885TLR9 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.